Krystal Biotech, Inc. Payments to Acquire Debt Securities, Available-for-sale
Krystal Biotech, Inc. (KRYS) reported Payments to Acquire Debt Securities, Available-for-sale of $422.54 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-02-17
- Krystal Biotech, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $72.46M, a 49.49% decline year-over-year.
- Krystal Biotech, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $98.37M, a 12.58% decline year-over-year.
- Krystal Biotech, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $113.90M, a 0.44% increase year-over-year.
- Krystal Biotech, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $137.81M, a 56.00% increase year-over-year.
- Krystal Biotech, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $422.54M, a 7.69% decline from fiscal 2024.
- Krystal Biotech, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $457.74M, a 10.03% decline from fiscal 2023.
- Krystal Biotech, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $508.78M, a 59.60% increase from fiscal 2022.
- Krystal Biotech, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $318.78M, a 67.37% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $72.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $170.84M derived: sum of 2 quarters · filed 2026-02-17 | $284.73M derived: sum of 3 quarters · filed 2026-02-17 | $422.54M 10-K · filed 2026-02-17 | ||
| 2025-09-30 | $98.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $212.27M derived: sum of 2 quarters · filed 2025-11-03 | $350.08M 10-Q · filed 2025-11-03 | $493.55M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2025-06-30 | $113.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $251.71M 10-Q · filed 2025-08-04 | $395.18M derived: sum of 3 quarters · filed 2026-02-17 | $507.71M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2025-03-31 | $137.81M 10-Q · filed 2025-05-06 | $281.28M derived: sum of 2 quarters · filed 2026-02-17 | $393.81M derived: sum of 3 quarters · filed 2026-02-17 | $507.21M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2024-12-31 | $143.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $256.00M derived: sum of 2 quarters · filed 2026-02-17 | $369.40M derived: sum of 3 quarters · filed 2026-02-17 | $457.74M 10-K · filed 2026-02-17 | ||
| 2024-09-30 | $112.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $225.93M derived: sum of 2 quarters · filed 2025-11-03 | $314.27M 10-Q · filed 2025-11-03 | $397.17M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2024-06-30 | $113.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $201.74M 10-Q · filed 2025-08-04 | $284.64M derived: sum of 3 quarters · filed 2026-02-17 | $390.54M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2024-03-31 | $88.33M 10-Q · filed 2025-05-06 | $171.24M derived: sum of 2 quarters · filed 2026-02-17 | $277.14M derived: sum of 3 quarters · filed 2026-02-17 | $451.54M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2023-12-31 | $82.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $188.81M derived: sum of 2 quarters · filed 2026-02-17 | $363.20M derived: sum of 3 quarters · filed 2026-02-17 | $508.78M 10-K · filed 2026-02-17 | ||
| 2023-09-30 | $105.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $280.29M derived: sum of 2 quarters · filed 2024-11-04 | $425.87M 10-Q · filed 2024-11-04 | $529.94M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-06-30 | $174.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $319.97M 10-Q · filed 2024-08-05 | $424.04M derived: sum of 3 quarters · filed 2025-02-19 | $491.50M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-03-31 | $145.58M 10-Q · filed 2024-05-06 | $249.65M derived: sum of 2 quarters · filed 2025-02-19 | $317.10M derived: sum of 3 quarters · filed 2025-02-19 | $401.60M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2022-12-31 | $104.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $171.53M derived: sum of 2 quarters · filed 2025-02-19 | $256.03M derived: sum of 3 quarters · filed 2025-02-19 | $318.78M 10-K · filed 2025-02-19 | ||
| 2022-09-30 | $67.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $151.96M derived: sum of 2 quarters · filed 2023-11-06 | $214.71M 10-Q · filed 2023-11-06 | $321.36M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-06-30 | $84.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $147.25M 10-Q · filed 2023-08-07 | $253.91M derived: sum of 3 quarters · filed 2024-02-26 | $278.16M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-03-31 | $62.75M 10-Q · filed 2023-05-08 | $169.41M derived: sum of 2 quarters · filed 2024-02-26 | $193.66M derived: sum of 3 quarters · filed 2024-02-26 | $253.22M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2021-12-31 | $106.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $130.90M derived: sum of 2 quarters · filed 2024-02-26 | $190.46M derived: sum of 3 quarters · filed 2024-02-26 | $190.46M 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $24.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $83.81M derived: sum of 2 quarters · filed 2022-11-07 | $83.81M 10-Q · filed 2022-11-07 | $83.81M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-06-30 | $59.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $59.56M 10-Q · filed 2022-08-08 | $38.10M 10-Q · filed 2021-08-09 | $59.56M derived: sum of 3 quarters · filed 2023-02-27 | $59.56M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $1.24M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $1.24M derived: sum of 3 quarters · filed 2023-02-27 | $3.21M 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $1.24M derived: sum of 2 quarters · filed 2021-11-08 | $3.21M 10-Q · filed 2021-11-08 | $4.93M derived: sum of 4 quarters · filed 2021-11-08 | ||
| 2020-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.21M 10-Q · filed 2021-08-09 | $3.19M 10-Q · filed 2020-08-07 | $4.93M derived: sum of 3 quarters · filed 2021-08-09 | $7.15M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $1.97M 10-Q · filed 2021-05-10 | $3.70M derived: sum of 2 quarters · filed 2021-05-10 | $5.91M derived: sum of 3 quarters · filed 2021-05-10 | $10.05M derived: sum of 4 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.95M derived: sum of 2 quarters · filed 2021-03-01 | $8.08M derived: sum of 3 quarters · filed 2021-03-01 | $8.60M 10-K · filed 2021-03-01 | $8.57M 10-K · filed 2020-03-10 | |
| 2019-09-30 | $2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $6.36M derived: sum of 2 quarters · filed 2020-11-09 | $6.87M 10-Q · filed 2020-11-09 | $9.33M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $4.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $4.65M 10-Q · filed 2020-08-07 | $7.11M derived: sum of 3 quarters · filed 2020-08-07 | $9.10M derived: sum of 4 quarters · filed 2020-08-07 | ||
| 2019-03-31 | $512.00K 10-Q · filed 2020-05-04 | $2.98M derived: sum of 2 quarters · filed 2020-05-04 | $4.96M derived: sum of 3 quarters · filed 2020-05-04 | |||
| 2018-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $4.45M derived: sum of 2 quarters · filed 2020-03-10 | $8.09M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $5.63M 10-Q · filed 2019-11-04 | ||||
| 2018-06-30 | $3.64M 10-Q · filed 2019-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |